Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19180809 | REGULATION OF ARTIFICIAL MIRNAS BY ENDOGENOUS TISSUE-SPECIFIC MIRNAS AND METHODS OF USING THE SAME | April 2025 | February 2026 | Abandon | 10 | 1 | 0 | No | No |
| 18948625 | BACULOVIRUS VECTOR AND USE THEREOF IN PREPARATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS (rAAV) IN INSECT CELL | November 2024 | December 2025 | Allow | 13 | 2 | 1 | Yes | No |
| 18936497 | METHODS USING SURFACE-EXPRESSIBLE ACTIVATABLE EPITOPES TO LOCALIZE AND/OR TREAT DISEASED CELLS | November 2024 | October 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18919103 | COMPOSITIONS FOR TREATING CANCER | October 2024 | July 2025 | Allow | 9 | 2 | 1 | Yes | No |
| 18913027 | COMPOSITION FOR REGULATING PRODUCTION OF PROTEINS | October 2024 | May 2025 | Allow | 7 | 1 | 0 | No | No |
| 18885902 | COMPOSITION FOR REGULATING PRODUCTION OF FUSION PROTEINS | September 2024 | May 2025 | Allow | 8 | 1 | 0 | No | No |
| 18738959 | COMPOSITION FOR REGULATING PRODUCTION OF FUSION PROTEINS | June 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18646835 | ADENO-ASSOCIATED VIRUS CAPSID | April 2024 | November 2025 | Allow | 18 | 3 | 0 | Yes | No |
| 18435722 | PRESERVATION OF PANCREATIC ISLET GRAFTS IN THE EXTRAHEPATIC SPACE | February 2024 | August 2025 | Allow | 19 | 3 | 0 | Yes | No |
| 18427711 | NON-TRANSGENE TRANSFECTION FOR THERAPEUTIC PURPOSES | January 2024 | June 2025 | Allow | 17 | 3 | 0 | Yes | No |
| 18474506 | Cross-Species Compatible Adeno-Associated Virus Compositions and Methods of Use Thereof | September 2023 | July 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18275591 | TARGETED EXTRACELLULAR VESICLES FOR DELIVERY OF THERAPEUTICS | August 2023 | October 2024 | Allow | 15 | 1 | 0 | No | No |
| 18351800 | ENGINEERED HUMAN-ENDOGENOUS VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS | July 2023 | November 2024 | Allow | 17 | 2 | 0 | Yes | No |
| 18351674 | ENGINEERED HUMAN-ENDOGENOUS VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS | July 2023 | November 2024 | Allow | 16 | 4 | 0 | Yes | No |
| 18351689 | ENGINEERED HUMAN-ENDOGENOUS VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS | July 2023 | November 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18322531 | METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF | May 2023 | January 2024 | Allow | 8 | 2 | 0 | No | No |
| 18316899 | VIRAL VECTORS FOR CANCER THERAPY | May 2023 | May 2025 | Allow | 24 | 3 | 0 | Yes | No |
| 18098456 | HYPOTHERMIC PRESERVING DILUENT, HYPOTHERMIC PRESERVING METHOD OF PLECTROPOMUS LEOPARDUS SEMEN AND APPLICATION THEREOF | January 2023 | March 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18093119 | POLYNUCLEOTIDE SECONDARY STRUCTURE | January 2023 | March 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18008674 | ARTIFICIAL NON-CODING RNA MODULE FOR ENHANCING NITROGEN FIXATION ABILITY OF MICROORGANISMS | December 2022 | January 2025 | Allow | 25 | 2 | 0 | Yes | No |
| 18000174 | BISPECIFIC ANTIBODY AGAINST CLDN18.2 AND CD3 | November 2022 | January 2026 | Abandon | 37 | 0 | 1 | No | No |
| 17936023 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | September 2022 | June 2025 | Allow | 33 | 0 | 0 | No | No |
| 17843916 | METHODS OF OBTAINING TUMOR-SPECIFIC T CELL RECEPTORS | June 2022 | May 2024 | Abandon | 23 | 4 | 0 | No | No |
| 17611726 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF TUMOR OR CANCER, AND APPLICATION THEREOF | May 2022 | March 2026 | Abandon | 52 | 0 | 1 | No | No |
| 17752436 | METHOD FOR REVERSING MULTIPLE RESISTANCE IN ANIMAL CELLS | May 2022 | September 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17660114 | DEFINED COMPOSITION GENE MODIFIED T-CELL PRODUCTS | April 2022 | August 2025 | Allow | 40 | 1 | 0 | No | No |
| 17769495 | CAL-T CONSTRUCTS AND USES THEREOF | April 2022 | January 2026 | Abandon | 45 | 2 | 0 | Yes | No |
| 17719473 | PHOTORECEPTORS AND PHOTORECEPTOR PROGENITORS PRODUCED FROM PLURIPOTENT STEM CELLS | April 2022 | October 2025 | Allow | 42 | 4 | 0 | No | Yes |
| 17707944 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | March 2022 | December 2025 | Allow | 45 | 8 | 1 | Yes | No |
| 17696978 | IL-36 CYTOKINE EXPRESSING ONCOLYTIC VIRUSES FOR TREATING CANCER | March 2022 | December 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17634050 | IMMUNE EFFECTOR CELL FOR CO-EXPRESSING CHEMOKINE RECEPTOR | February 2022 | December 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17581203 | NUCLEIC ACID MOLECULES CONTAINING SPACERS AND METHODS OF USE THEREOF | January 2022 | November 2025 | Allow | 46 | 1 | 0 | No | No |
| 17574118 | INTRANASAL ADMINISTRATION OF ADENO-ASSOCIATED VIRUS TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | January 2022 | July 2025 | Abandon | 42 | 1 | 0 | Yes | No |
| 17559538 | REGULATABLE ADENO-ASSOCIATED VIRUS (AAV) VECTOR | December 2021 | February 2026 | Allow | 49 | 1 | 1 | Yes | No |
| 17546951 | ANGIOGENIC CONDITIONING TO ENHANCE CARDIAC CELLULAR REPROGRAMMING OF FIBROBLASTS OF THE INFARCTED MYOCARDIUM | December 2021 | March 2026 | Abandon | 51 | 2 | 0 | No | No |
| 17543543 | MRNA THERAPY FOR ARGININOSUCCINATE SYNTHETASE DEFICIENCY | December 2021 | September 2025 | Allow | 45 | 2 | 0 | No | Yes |
| 17540377 | Compositions and Methods for Treating Cancer with DuoCARs | December 2021 | March 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17614327 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | November 2021 | February 2026 | Allow | 51 | 2 | 1 | Yes | No |
| 17605976 | ALLOGENEIC CAR-T CELL, PREPARATION THEREFOR, AND APPLICATION THEREOF | October 2021 | September 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17498520 | ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY | October 2021 | January 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17493032 | Antigen Binding Regions Against Fibronectin Type III Domains and Methods of Using the Same | October 2021 | November 2024 | Allow | 38 | 0 | 0 | Yes | No |
| 17599750 | ADENO-ASSOCIATED VIRUS WITH ENGINEERED CAPSID | September 2021 | January 2026 | Allow | 52 | 1 | 1 | No | No |
| 17483484 | Universal Killer T-Cell | September 2021 | September 2025 | Abandon | 47 | 2 | 0 | Yes | No |
| 17472037 | AAV-EPO FOR TREATING COMPANION ANIMALS | September 2021 | January 2026 | Allow | 52 | 2 | 0 | Yes | Yes |
| 17458044 | NON-DISRUPTIVE GENE TARGETING | August 2021 | January 2026 | Abandon | 53 | 2 | 0 | No | Yes |
| 17386063 | FABRY DISEASE GENE THERAPY | July 2021 | April 2025 | Allow | 44 | 2 | 0 | No | No |
| 17371546 | ONCOLYTIC ADENOVIRUS COMPOSITIONS | July 2021 | December 2025 | Allow | 53 | 1 | 1 | Yes | No |
| 17369168 | GENE THERAPIES FOR LYSOSOMAL DISORDERS | July 2021 | November 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17358904 | HELPER-DEPENDENT ADENOVIRAL GENE THERAPY DELIVERY AND EXPRESSION SYSTEM | June 2021 | February 2026 | Allow | 55 | 3 | 0 | No | No |
| 17350971 | PRIMING OF AN IMMUNE RESPONSE | June 2021 | March 2026 | Abandon | 57 | 3 | 0 | No | No |
| 17337018 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-BCMA IMMUNOTHERAPY | June 2021 | April 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17331733 | Compositions and Methods for Treating Cancer with Anti-CD38 Immunotherapy | May 2021 | March 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17332470 | COMPOSITIONS AND METHODS FOR REPROGRAMMING DISEASED MUSCULOSKELETAL CELLS | May 2021 | August 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17297380 | T Cell Modification | May 2021 | December 2025 | Allow | 54 | 3 | 1 | No | No |
| 17317025 | RETROVIRAL PARTICLE COMPRISING AT LEAST TWO ENCAPSIDATED NONVIRAL RNAS | May 2021 | August 2025 | Abandon | 51 | 3 | 0 | No | No |
| 17291947 | RNA CANCER VACCINES | May 2021 | February 2026 | Allow | 58 | 3 | 0 | Yes | No |
| 17245952 | DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS | April 2021 | December 2024 | Allow | 44 | 1 | 0 | No | No |
| 17284779 | PLASMID CONTAINING A SEQUENCE ENCODING AN MRNA WITH A SEGMENTED POLY(A) TAIL | April 2021 | January 2026 | Allow | 57 | 2 | 1 | Yes | No |
| 17206878 | Intrathecal Delivery of Recombinant Adeno-Associated Virus 9 | March 2021 | September 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17193030 | RECOMBINANT AAV VECTORS USEFUL FOR REDUCING IMMUNITY AGAINST TRANSGENE PRODUCTS | March 2021 | July 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17180159 | DNA PRESERVATION IN BIOLOGICAL SPECIMENS USING METAL CHELATORS | February 2021 | August 2025 | Allow | 53 | 3 | 0 | No | No |
| 17264911 | TAG72 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF TAG72-POSITIVE TUMORS | February 2021 | December 2024 | Allow | 46 | 1 | 0 | Yes | No |
| 17150858 | METHODS FOR GENERATING ANIMALS WITH DESIRABLE TRAITS | January 2021 | February 2025 | Allow | 49 | 2 | 0 | No | No |
| 17139097 | COMPOSITIONS AND METHODS FOR TREATING DISEASES | December 2020 | October 2024 | Abandon | 46 | 2 | 0 | No | No |
| 17139618 | IMMUNE CELL TREATMENT OF NERVE DAMAGE | December 2020 | February 2026 | Abandon | 60 | 4 | 0 | No | No |
| 17256812 | ANC80 ENCODING SPHINGOLIPID-METABOLIZING PROTEINS | December 2020 | December 2025 | Allow | 60 | 2 | 1 | No | No |
| 17124922 | Chimeric Growth Factor Receptors | December 2020 | June 2025 | Abandon | 54 | 2 | 1 | Yes | No |
| 17253491 | POLYNUCLEOTIDE | December 2020 | January 2025 | Abandon | 49 | 3 | 0 | No | No |
| 15733815 | USES AND METHODS FOR ONCOLYTIC VIRUS TARGETING OF IL-4/IL-13 AND FUSIONS THEREOF | November 2020 | April 2025 | Allow | 53 | 3 | 0 | Yes | No |
| 17044085 | PRODUCTION OF BROWN ADIPOCYTES | September 2020 | June 2024 | Allow | 44 | 2 | 0 | Yes | No |
| 17040009 | CHIMERIC TRANSMEMBRANE PROTEINS AND USES THEREOF | September 2020 | December 2024 | Allow | 51 | 2 | 1 | No | No |
| 17018088 | NON-CODING IMMUNOMODULATORY DNA CONSTRUCT | September 2020 | October 2024 | Abandon | 49 | 2 | 0 | No | No |
| 17008086 | ARTIFICIAL ANTIGEN PRESENTING CELLS HAVING A DEFINED AND DYNAMIC SHAPE | August 2020 | June 2025 | Abandon | 58 | 3 | 0 | No | No |
| 16989307 | ALIGNED FIBER AND METHOD OF USE THEREOF | August 2020 | August 2024 | Allow | 48 | 2 | 0 | Yes | No |
| 16968602 | METHODS FOR SCREENING VARIANT OF TARGET GENE | August 2020 | January 2025 | Allow | 53 | 2 | 0 | Yes | No |
| 16943335 | Altering Gene Expression in CART Cells and Uses Thereof | July 2020 | February 2025 | Allow | 55 | 3 | 1 | Yes | No |
| 16965895 | USE OF LENTIVIRAL VECTORS EXPRESSING FACTOR VIII | July 2020 | March 2025 | Allow | 55 | 4 | 0 | No | No |
| 16923606 | Electroporation Devices And Methods Of Cell Transfection | July 2020 | July 2024 | Allow | 49 | 3 | 1 | Yes | No |
| 16921783 | COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION | July 2020 | May 2025 | Abandon | 59 | 4 | 0 | No | No |
| 16917008 | GENERATION OF INDUCED PLURIPOTENT STEM CELLS FROM NORMAL HUMAN MAMMARY EPITHELIAL CELLS | June 2020 | February 2026 | Abandon | 60 | 5 | 0 | Yes | No |
| 16895874 | CHIMERIC PROTEIN TOXINS FOR EXPRESSION BY THERAPEUTIC BACTERIA | June 2020 | March 2025 | Allow | 58 | 5 | 1 | Yes | No |
| 16880402 | Controlled Transgene Expression in Regulatory T Cells | May 2020 | May 2024 | Allow | 48 | 4 | 1 | Yes | Yes |
| 16758990 | MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES | April 2020 | January 2026 | Allow | 60 | 6 | 1 | No | No |
| 16823319 | METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING AND EXPANDING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF | March 2020 | November 2025 | Allow | 60 | 2 | 1 | Yes | No |
| 16818477 | Conditional Modulation of Therapy Using Recombinant Cells | March 2020 | August 2025 | Allow | 60 | 5 | 1 | No | No |
| 16807254 | Collection, Genome Editing, And Washing Of T-Cell Lymphocytes | March 2020 | August 2024 | Allow | 53 | 3 | 0 | Yes | No |
| 16746257 | TARGETED AND MODULAR EXOSOME LOADING SYSTEM | January 2020 | January 2026 | Abandon | 60 | 5 | 1 | Yes | No |
| 16610883 | GENE THERAPY FOR CILIOPATHIES | November 2019 | July 2024 | Allow | 56 | 4 | 1 | Yes | No |
| 16594017 | Methods for the Delivery of Therapeutic Agents to Donor Organs | October 2019 | February 2026 | Allow | 60 | 7 | 0 | No | No |
| 16498369 | SHRNA EXPRESSION CASSETTE, POLYNUCLEOTIDE SEQUENCE CARRYING SAME, AND APPLICATION THEREOF | September 2019 | December 2024 | Abandon | 60 | 5 | 1 | No | No |
| 16490702 | METHODS FOR DETERMINING POTENCY OF ADENO-ASSOCIATED VIRUS PREPARATIONS | September 2019 | January 2026 | Allow | 60 | 7 | 1 | Yes | No |
| 16537192 | NUCLEIC ACID MOLECULES AND USES THEREOF FOR NON-VIRAL GENE THERAPY | August 2019 | July 2024 | Allow | 59 | 4 | 1 | Yes | Yes |
| 16502859 | MICROFLUIDIC DEVICES, SYSTEMS, INFRASTRUCTURES, USES THEREOF AND METHODS FOR GENETIC ENGINEERING USING SAME | July 2019 | March 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16409406 | COMPOSITIONS FOR THE INACTIVATION OF VIRUS REPLICATION AND METHODS OF MAKING AND USING THE SAME | May 2019 | May 2025 | Abandon | 60 | 4 | 0 | Yes | No |
| 16405285 | ONCOLYTIC ADENOVIRUSES FOR TREATING CANCER | May 2019 | June 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 16336429 | METHODS OF ADOPTIVE CELL THERAPY | March 2019 | December 2025 | Abandon | 60 | 6 | 1 | No | No |
| 16332315 | DELIVERY OF NUCLEIC ACIDS, PROTEINS AND SMALL MOLECULES IN VITREOUS VESICULAR BODIES | March 2019 | January 2026 | Allow | 60 | 4 | 1 | No | No |
| 16326126 | METHODS AND COMPOSITIONS FOR TARGETED GENE TRANSFER | February 2019 | February 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16325679 | CRISPR-CAS GENOME ENGINEERING VIA A MODULAR AAV DELIVERY SYSTEM | February 2019 | February 2026 | Allow | 60 | 9 | 1 | Yes | No |
| 16318965 | COMPOSITIONS AND METHODS FOR STUDYING THE TAT GENE | January 2019 | April 2025 | Allow | 60 | 4 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MARVICH, MARIA.
With a 80.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 28.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MARVICH, MARIA works in Art Unit 1634 and has examined 178 patent applications in our dataset. With an allowance rate of 83.1%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 53 months.
Examiner MARVICH, MARIA's allowance rate of 83.1% places them in the 57% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by MARVICH, MARIA receive 3.41 office actions before reaching final disposition. This places the examiner in the 93% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by MARVICH, MARIA is 53 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +8.7% benefit to allowance rate for applications examined by MARVICH, MARIA. This interview benefit is in the 39% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 20.6% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 42.0% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 86.1% of appeals filed. This is in the 79% percentile among all examiners. Of these withdrawals, 80.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 81.8% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 27.0% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 12.2% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.